$RAPH
Raphael Pharmaceutical Inc.

2023 Q2 Form 10-Q Financial Statement

#000121390023065005 Filed on August 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2022 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $293.0K $86.00K
YoY Change 248.81%
% of Gross Profit
Depreciation & Amortization $0.00
YoY Change
% of Gross Profit
Operating Expenses $293.0K $86.00K
YoY Change 248.81%
Operating Profit -$419.0K -$175.0K
YoY Change -31.54%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.000K -$10.00K
YoY Change -113.33%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$417.0K -$185.0K
YoY Change -33.49% -27.45%
Net Earnings / Revenue
Basic Earnings Per Share $0.03 $0.01
Diluted Earnings Per Share $0.03 $0.01
COMMON SHARES
Basic Shares Outstanding 16.08M shares 13.04M shares
Diluted Shares Outstanding 16.11M shares 13.04M shares

Balance Sheet

Concept 2023 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $111.0K $81.00K
Short-Term Investments
Other Short-Term Assets $7.000K
YoY Change -88.52%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $118.0K
YoY Change -39.8%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.000K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $118.0K
Total Long-Term Assets $1.000K
Total Assets $119.0K
YoY Change -39.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $180.0K
YoY Change 130.77%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $180.0K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$6.707M
YoY Change 92.79%
Common Stock $164.0K
YoY Change 14.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$61.00K $103.0K
YoY Change
Total Liabilities & Shareholders Equity $119.0K
YoY Change -39.29%

Cashflow Statement

Concept 2023 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$417.0K -$185.0K
YoY Change -33.49% -27.45%
Depreciation, Depletion And Amortization $0.00
YoY Change
Cash From Operating Activities -$82.00K
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $10.00K
YoY Change
NET CHANGE
Cash From Operating Activities -$82.00K
Cash From Investing Activities
Cash From Financing Activities $10.00K
Net Change In Cash $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$82.00K
Capital Expenditures
Free Cash Flow -$82.00K
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53002
dei Entity Registrant Name
EntityRegistrantName
Raphael Pharmaceutical Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-0204284
dei Entity Address Address Line1
EntityAddressAddressLine1
4 Lui Paster Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Tel Aviv-Jaffa
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
6803605
dei City Area Code
CityAreaCode
(+972)
dei Local Phone Number
LocalPhoneNumber
52-775-5072
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
16368168 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
288000 usd
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
7000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
43000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
118000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
331000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2000 usd
CY2023Q2 us-gaap Assets
Assets
119000 usd
CY2022Q4 us-gaap Assets
Assets
333000 usd
CY2023Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
141000 usd
CY2022Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
224000 usd
CY2023Q2 us-gaap Notes Payable Current
NotesPayableCurrent
39000 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
3000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
180000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
227000 usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
21020560 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16368168 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
16368168 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15624040 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15624040 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
164000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
157000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6482000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5975000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6707000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6026000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
333000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
407000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
293000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
270000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
617000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
126000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
528000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-677000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-787000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-419000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-612000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-15000 usd
us-gaap Net Income Loss
NetIncomeLoss
-681000 usd
us-gaap Net Income Loss
NetIncomeLoss
-812000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-417000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-627000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.05
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16037214 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13342679 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
16109514 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13647151 shares
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
106000 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
149000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-264000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-9000 usd
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
165000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-417000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
128000 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
161000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-185000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
103000 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
352000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
290000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-627000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
118000 usd
us-gaap Profit Loss
ProfitLoss
-681000 usd
us-gaap Profit Loss
ProfitLoss
-812000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
200000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
290000 usd
us-gaap Depreciation
Depreciation
1000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-36000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-258000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-170000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-66000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-614000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-330000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
314000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
312000 usd
raph Advance Payment On Account Of Shares
AdvancePaymentOnAccountOfShares
123000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
437000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
312000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-177000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
288000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
153000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135000 usd
CY2020Q4 raph Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2020Q4 raph Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100 shares
CY2021Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
9459253 shares
CY2021Q2 raph Issued And Outstanding Share Capital Percentage
IssuedAndOutstandingShareCapitalPercentage
0.90 pure
CY2021Q2 us-gaap Shares Issued
SharesIssued
1051028 shares
CY2021Q2 raph Common Stock Percentage
CommonStockPercentage
0.10 pure
CY2023Q2 us-gaap Retained Earnings Unappropriated
RetainedEarningsUnappropriated
6706000 usd
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
255750 shares
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
1.13
CY2023Q1 us-gaap Equity Method Investment Aggregate Cost
EquityMethodInvestmentAggregateCost
117000 usd
CY2023Q1 us-gaap Equity Method Investment Quoted Market Value
EquityMethodInvestmentQuotedMarketValue
250000 usd
CY2023Q2 raph Company Raised Amount
CompanyRaisedAmount
190000 usd
CY2023Q2 us-gaap Transfer To Investments
TransferToInvestments
123000 usd
CY2023Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
201000 shares
CY2023Q2 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
200000 usd
us-gaap Depreciation
Depreciation
usd
raph Advance Payment On Account Of Shares
AdvancePaymentOnAccountOfShares
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001415397

Files In Submission

Name View Source Status
0001213900-23-065005-index-headers.html Edgar Link pending
0001213900-23-065005-index.html Edgar Link pending
0001213900-23-065005.txt Edgar Link pending
0001213900-23-065005-xbrl.zip Edgar Link pending
f10q0623ex31-1_raphael.htm Edgar Link pending
f10q0623ex31-2_raphael.htm Edgar Link pending
f10q0623ex32-1_raphael.htm Edgar Link pending
f10q0623ex32-2_raphael.htm Edgar Link pending
f10q0623_raphaelpharma.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
raph-20230630.xsd Edgar Link pending
report.css Edgar Link pending
raph-20230630_cal.xml Edgar Link unprocessable
raph-20230630_def.xml Edgar Link unprocessable
raph-20230630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
raph-20230630_pre.xml Edgar Link unprocessable
f10q0623_raphaelpharma_htm.xml Edgar Link completed
Show.js Edgar Link pending